Lipid nanoparticles for mRNA therapy: recent advances in targeted delivery

References

[1] Xiao Y, Tang Z, Huang X, et al. Emerging mRNA technologies: delivery strategies and biomedical applications. Chem Soc Rev 2022;51:3828–45.

[2] Kong N, Zhang R, Wu G, et al. Intravesical delivery of KDM6A-mRNA via mucoadhesive nanoparticles inhibits the metastasis of bladder cancer. Proc Natl Acad Sci USA 2022;119:e2112696119.

[3] Rurik JG, Tombácz I, Yadegari A, et al. CAR T cells produced in vivo to treat cardiac injury. Science 2022;375:91–6.

[4] Dammes N, Goldsmith M, Ramishetti S, et al. Conformation-sensitive targeting of lipid nanoparticles for RNA therapeutics. Nat Nanotechnol 2021;16:1030–8.

[5] Su FY, Zhao QH, Dahotre SN, et al. In vivo mRNA delivery to virus-specific T cells by light-induced ligand exchange of MHC class I antigen-presenting nanoparticles. Sci Adv 2022;8:eabm7950.

[6] Han X, Zhang H, Butowska K, et al. An ionizable lipid toolbox for RNA delivery. Nat Commun 2021;12:7233.

[7] Sago CD, Lokugamage MP, Paunovska K, et al. High-throughput in vivo screen of functional mRNA delivery identifies nanoparticles for endothelial cell gene editing. Proc Natl Acad Sci USA 2018;115:e9944–52.

[8] Cheng Q, Wei T, Farbiak L, et al. Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing. Nat Nanotechnol 2020;15:313–20.

[9] Liu S, Cheng Q, Wei T, et al. Membrane-destabilizing ionizable phospholipids for organ-selective mRNA delivery and CRISPR-Cas gene editing. Nat Mater 2021;20:701–10.

[10] Dilliard SA, Cheng Q, Siegwart DJ. On the mechanism of tissue-specific mRNA delivery by selective organ targeting nanoparticles. Proc Natl Acad Sci USA 2021;118:e2109256118.

RIGHTS & PERMISSIONS

The Author(s) 2022